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Experience with liver transplantation over a period of II years at the 
University of Pittsburgh is presented. The application of liver transplanta-
tion to cases of hepatocellular carcinoma has changed considerably over 
this II-year period with the sequential introduction of adjuvant and. more 
recently. neoadjuvant chemotherapy. 
Results with the combination of chemotherapy plus surgery appear to be 
better than results with either agent alone. Moreover. the early results with 
neoadjuvant therapy appear to be better than those achieved with adjuvant 
therapy. 
As a result of this experience. conceptual changes in the approach to the 
problem of hepatic cancer and the role of both chemotherapy and liver 
transplantation in its management have changed at the University of Pitts-
burgh. These changes are identified and discussed. 
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INTRODUCTION 
During the first part of the II-year interval encompass-
ing this report. orthotopic liver transplantation (OL Tx) as 
a therapy for primary liver cancer was perceived as the 
only therapy with any hope of clinical success. The posi-
tion currently held is that liver cancer is a relative con-
traindication for liver transplantation [1-4]. This change 
in the willingness of physicians and surgeons to submit 
their patients to liver transplantation for the indication of 
primary hepatic cancer has come about as a direct result 
of: I) an analysis of the effectiveness of the procedure for 
this condition: 2) the increasing application of liver transp 
plantation for other disease indications having a better 
long-term patient survival: and 3) less donor organ avail-
ability for liver transplantation. Much of the experience 
obtained in Pittsburgh with OL Tx for primary hepatic 
cancer has affected the enthusiasm of newer liver trans-
plant programs to include hepatic cancer as an indication 
for transplantation. The following is a report of the expe-
rience at Pittsburgh with OLTx for primary hepatic can-
cer. It is presented so that the changes that have occurred 
Q 1993 Wiley-Liss, Inc. 
in the application of OL Tx at this center can be viewed 
both in their entirety and across time. 
METHODS 
The records for the II-year period from January I. 
1981 through December 31. 1991 for the application of 
OL Tx for primary hepatic cancer at the University of 
Pittsburgh were viewed using the TIMY system [5]. The 
overall experience for this II-year period was deter-
mined. and then the same data were re-analyzed examin-
ing the data for three specific time periods during which 
no chemotherapy was used. adjuvant chemotherapy was 
used. and. most retently. when neoadjuvant chemother-
apy was used: the results of such therapy were utilized to 
select patients for OL Tx. For each period. the number of 
cases transplanted and the patient survival curves were 
determined. as were the type and size of the primary liver 
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TABLE I. Types of Tumors for Which Liver Transplantation Was Performed in the Three 
Periods Studied 
Type of tumors ( 1981-1986) 
Hepatocellular carcinoma 15 
Cholangiolar carcinoma 10 
Mixed tumor 0 
Fibrolamellar 6 
Epithelio hemangio endothelioma 6 
Angiosarcoma I 
Hepatoblastoma 0 
Other 0 
Totals 37 
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Fig. I. Patient survi val for the 181 patients transplanted for a hepato-
biliary malignancy from January I. 1981 through December 31. 1991 
at the University of Pittsburgh. 
tumor when examined at the time of histopathologic as-
sessment of the resected whole liver. 
RESULTS 
During the study period. January I. 1981 through De-
cember 3 I. 199 I. a total of 18 I patients received a Ii ver 
transplant for a malignant disease (identified in Table I). 
A total of 37 cases were transplanted in the first period 
from January I. 1981 through December 31. 1986; a total 
of 89 were transplanted in the second period. January I. 
1987 through December 31. 1989: finally. a total of 54 
patients were transplanted in the period from January I. 
1990 through December 31. 1991. Although there was 
considerable variation from year to year in the type of 
cases transplanted for malignant disease when segregated 
as to time periods of interest. the types of cases were 
essentially identical (Table I). 
The patient survival curves for the cases included in 
this report are shown in Figures I and 2. Figure 2 demon-
strates the overall patient survival curve for the II-year 
period of interest. The 50% survival point is at 18 
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Fig. 2. Patient survival for the 181 patients transplanted as noted in 
Figure I for each of the three leading dlsease-spectfic indications tor 
OL Tx for hepatic neoplastic disease. 
months. The 4-year survival is 30%. and 18% appear to 
be cured, with a survival of >6 years following OL Tx. 
When the survivals for the three most frequently trans-
planted types of primary hepatic malignancies are exam-
ined (Fig. 2). it can be seen that the experiences for three 
types of tumors <lre quite different. Specifically, a 50% 
survival for fibrolamellar carcinoma occurs at 34 months. 
while a 50% survival for cholangiolar carcinoma is seen 
at 12 months and for hepatoma at 18 months. 
The survival curve for the first period of the Pittsburgh 
experience from January 1981 through December 1986, 
when chemotherapy was not utilized. is shown in Figures 
3 and 4. The overall 50% survival was approximately 15 
months for all cases combined but was almost twice as 
long for those transplanted for a tibrolamellar carcinoma 
as compared with those transplanted for a primary hep-
atoma or cholangiolar carcinoma. The results for these 
latter two tumors were nearly identical. with a 50% sur-
vival at approximately 1 year. 
Once chemotherapy was instituted as part of the ap-
proach to these tumors. survival began to improve as 
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Fig. 3. Patienl survival curve for cases transplanted for hepatic ma-
lignancy during the period from January I. 1981 through December 
3 I. 1986. 
~ 
co 
K~ 
c: 
::l 
en 
1: 
(1) 
"" tV 
a. 
100 ... 
80 
60 
40 
20 
............ 
-- Hepatoma 
."-'" Fibralamallar carcinoma 
_._- Chalangiocarcinoma 
................................ , 
l~~~~~~~~~~~~~~~~~~~-g 
o 12 24 36 48 60 72 84 96 108 120 132 144 
Months After Transplantation 
Fig. 4. Patient survival curve for the cases transplanted for the three 
major Iypes of hepatIc malignancy in the series noted in Figure I. The 
solid line represents the data for cases With hepatocellular carcmoma: 
Ihe regular broken line represents the data for cases with fibrolamellar 
carcinoma: and the irregular broken line represents the data for cases 
with cholangiolar carcinoma. 
shown in Figures 5 and 6. The overall survival rate was 
still only at the level of 50% at 17 months. However, 
changes were occurring in the response of individual 
tumor types. 
Specifically, the 50% survival for patients transplanted 
for hepatoma had increased to 20 months. while the 50% 
survival for those with fibrolamellar tumors declined to 
16 months. No change in the prognosis for cases trans-
planted for cholangiolar carcinoma was evident. 
For the most part, when both pre- and post-OL Tx 
chemotherapy were utilized and the response to chemo-
therapy used to identify cases for OLTx, overall survival 
was increased to 19 months, and the largest gain appears 
to have occurred in the cases with cholangiolar carcinoma 
(Figs. 7 and 8). 
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Fig. 5. Patient survival curve for cases transplanted for hepatic ma-
lignancy during the period from January I. 1987 through December 
31. 1989. 
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Fig. 6. Patient survival curve for the cases transplanled for the three 
major types of hepatic malignancy in the series noted in Figure 4. The 
solid line represents the data for cases with hepatocellular carcinoma: 
the regular broken line represents the data for cases With fibrolamellar 
carcinoma: and the irregular broken line represents the data for cases 
with cholangiolar carcinoma. 
DISCUSSION 
The role of OL Tx in the treatment of hepatocellular 
carcinoma has evolved from a treatment offered in des-
peration to an individual with no other hope for survival 
or medical care in the 1960s and 1970s to a procedure 
offered only to a highly selected group based upon re-
strictive criteria developed as a consequence of empiric 
observation over almost 3 decades of study. 
Specifically, for nearly 21f2 decades, from 1963 
through 1986, patients with hepatic cancer were consid-
ered to be the ideal patients for OLTx, as no other therapy 
existed that had potential for a cure let alone a disease-
free interval prior to the patient's death [1.2.4.6]. This 
situation was true world-wide as well as in Pittsburgh 
from the inception of the program in 1981 through the 
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Fig. 7. Patient survival curve for cases transplanted for hepatic ma-
lignancy during the period from January I. 1990 through December 
31. 1991. 
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Fig. 8. Patient survIval curve for the cases transplanted for the three 
major types of hepatic malignancy in the series noted in Figure 7. The 
solid line represents the data for cases transplanted for hepatocellular 
carcinoma while the broken line represents the data for cases with 
cholangiolar carcinoma. 
first 5 years of the program. During this period. several 
facts became evident: I) essentially all cases (>80%) 
recurred by I year; and 2) nearly all cases died within 2 
years (>70%). with only a minority surviving beyond 2 
years with no evidence of disease (-30%), A closer 
examination of this data revealed several additional 
facts--first. that the incidental lesions. those <5 cm in 
diameter and those discovered as a result of a pathologic 
examination of the resected liver not originally thought to 
have a tumor but nonetheless having one. were the only 
cases to be cured. with a cure defined as a patient being 
alive and disease free beyond 2 years from the date of 
transplantation [6-9]. The second finding was that the 
patients with bilobar disease. lymphatic metastasis. and 
vascular invasion documented pathologically by exami-
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nation of the resected liver did worse (recurred within I 
year) as compared with those who did not have these 
conditions [8-10]. 
Based upon these findings, two important recommen-
dations were made that affected changes in the field. The 
first was the recommendation that small tumors, those 
that would have been classified as incidental tumors ear-
lier. be treated preferentially with OLTx, as the recur-
rence rate with a major hepatic resection was 60% at 2 
years while it was well below 5% when treated with total 
hepatectomy and OL Tx [9]. This recommendation has 
not yet been implemented widely because of its presumed 
excessively aggressive approach but is gradually becom-
ing more widely accepted by transplant centers world-
wide. The second recommendation was that large tumors 
(>5 cm diameter). should they be submitted to OLTx. 
should receive adjuvant chemotherapy to treat microme-
tastasis that would otherwise have escaped resection and 
would ultimately lead to the death of the patient in ques-
tion. The simultaneous development of chemotherapeutic 
agents reported to be effective in at least some cases of 
primary hepatic cancer has allowed this latter recommen-
dation to proceed to fruition. Despite the application of 
adjuvant chemotherapy, disease recurrence still occurred 
and led inevitably to the loss of patient life. This was the 
state of the art during the middle period in Pittsburgh 
( 1987-1989) and most other large transplant centers that 
were still accepting tumor patients for OLTx. 
The most recent period ( 1989 to the present) grew out 
of the experience of the middle period with adjuvant 
chemotherapy, as investigators began to use chemother-
apy prior to. as well as after OLTx (neoadjuvant) rather 
than simply after the transplant procedure (adjuvant). 
With this approach. three groups of patients with hepatic 
cancer being considered for OL Tx became clinically rec-
ognizable: 1) those who experienced a true oncologic 
response to the neoadjuvant chemotherapy. with a 50% 
or greater reduction in their tumor burden: 2) those who 
appeared to respond to the chemotherapy but did not meet 
the criteria for a true response with less than a 50% 
reduction of the tumor burden: and 3) those who failed to 
respond to the chemotherapy altogether. When OL Tx 
was applied to the first group. 2-year survival rates 
jumped dramatically to 86% from a pre-neoadjuvant level 
of 40% if the chemotherapy was continued post-opera-
tively for a full three cycles [7]. For those who failed to 
achieve an oncologic remission but responded. the che-
motherapy has been continued continuously at monthly 
intervals. Some of these latter cases. after a full year of 
such therapy. have had no additional disease progression 
and have been transplanted after I year of chemotherapy 
and stable disease. The results in this group are as yet too 
small to be anything but anecdotal but appear to be quite 
promising. For those failing to respond to chemotherapy. 
the chemotherapy has been stopped and either a-inter-
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feron or honnonal therapy. principally tamoxifen. has 
been used. As expected. the results in this latter group 
have been quite poor, with only four survivors beyond 
3-4 months of secondary therapy. 
The observations that hepatic resections for primary 
hepatoma have only a 40% survival rate as compared 
with an essentially 100% 2-year survival rate for inciden-
tal lesions with OLTx alone and an 86% survival at 2 
years for clinically obvious tumors showing a response to 
chemotherapy and OL Tx has dramatically changed the 
thinking about the role of hepatic resection (subtotal re-
sections) and OLTx in the management of primary liver 
cancer. 
Based upon the recent experience with neoadjuvant 
chemotherapy and the role of total hepatectomy for inci-
dental lesions «5 cm in diameter). it may be best to 
pursue the following course: 
I. Utilize OLTx for all small tumors <5 cm in diame-
ter 
2. Utilize neoadjuvant chemotherapy for three cycles 
in all cases with tumors> 5 cm in diameter 
3. Transplant those responding to the chemotherapy 
and continue the chemotherapy for another three 
cycles post-OL Tx 
4. Continue on the chemotherapy for a full I year 
those having a partial response to the chemotherapy 
but not achieving the predetermined criteria of a 
full response (>50% reduction in tumor volume). 
Completely re-evaluate those continuing to have a 
partial response and stable disease for the presence 
of extra-hepatic disease and if none is found. pro-
ceed to OLTx. Obviously. those with extrahepatic 
disease should be rejected for any further consider-
ation for OLTx but should continue to receive the 
chemotherapy until the tumor develops clinical re-
sistance to the therapy. as evidenced by the devel-
opment of overt tumor progression 
5. Deny OL Tx to those failing to respond to the che-
motherapy and offer some experimental therapy 
other than chemotherapy 
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